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Abstract
Dementia associated with the Alzheimer’s disease is thought to be correlated with the con-
version of the β − Amyloid (Aβ) peptides from soluble monomers to aggregated oligomers
and insoluble fibrils. We present a discrete-time mathematical model for the aggregation of
Aβmonomers into oligomers using concepts from chemical kinetics and population dynam-
ics. Conditions for the stability and instability of the equilibria of the model are established. A
formula for the number of monomers that is required for producing oligomers is also given.
This may provide compound designers a mechanism to inhibit the Aβ aggregation.
Introduction
Alzheimer’s disease (AD) is the most cause of dementia and the most prevalent neurode-
generative disorder [1, 2, 3]. It is a progressive degenerative disorder that is age-related and is
characterized by the loss of synapses and neurons from the brain and by the presence of extra-
cellular protein-containing deposits (senile plaques) and intracellular neurofibrillary tangles
[4, 2]. Β − Amyloid is the principal protein component of the extracellular plaques. Aβ is a 39-
to 43- residue proteolytic product of a parental amyloid precursor protein (APP) that localizes
to the plasma membrane, trans-Golgi network, endoplasmic reticulum (ER) and endosomal,
lysosomal and mitochondrial membranes [5, 6]. Aβ contains sequences from extracellular and
transmembrane regions of the parent protein [7, 8]. The spontaneous conversion of Aβ mono-
mers into febrillar aggregates is found to be associated with the development of AD [9]. In fact,
the neurodegenerative effects of AD are hypothesized to arise from Aβ. This is commonly
known as the amyloid hypothesis, and is the dominant model of AD pathogenesis [10, 11, 5,
12, 13, 14, 15]. Albeit, amounting support from biochemical, genetic, and transgenic animal
studies that supports the amyloid hypothesis, [16, 17, 18, 19, 20], debate over the amyloid
hypothesis remains controversial.
In general, protein aggregation from soluble to non-soluble structures has been linked to be
a causative factor of several diseases, including AD, Parkinson’s disease, Huntington’s disease,
Prion disease, among others [21, 15]. For the case of Aβ linkage to AD, it has been found that
Aβ becomes indeed toxic once aggregated [22, 23, 24, 25, 26]. Furthermore, numerous studies
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show a strong correlation between soluble Aβ oligomer levels and the extent of synaptic loss
[27, 28, 29, 30, 31, 32], further suggesting that the soluble oligomers are the causative agents of
AD [33, 34, 35, 36]. This in turn has motivated several studies aimed at exploiting Aβ aggrega-
tion mechanisms and kinetics of Aβ conversion. Especially that synthetic Aβ was found to
spontaneously aggregates into sheet-rich fibrils, resembling those in plaques [5].
Naiki and Nakakuki [37] proposed a simple mathematical model in which fibril elongation
is postulated to occur by reversible addition of monomers to preexisting fibrils. The model,
however, does not explain the generation of new fibrils neither it simulates fibril length. Loma-
kin [38] proposed a detailed kinetic model in which they postulated that rapid reversible equi-
librium between monomers and micelles occurs, followed by spontaneous generation of
nuclei from micelles, in an irreversible process. Fibrils then grew by adding monomers to the
fibril tip or the nucleous. The model accounts for the co-existence of monomers and fibrils
and is capable of predicting fibril evolution (mass and length) in time. However, the experi-
ments leading to the model development were performed in non-physiological conditions (pH
1). Pallitto [3] developed a kinetic model that qualitatively de-scribed Aβ self-association kinet-
ics from the unfolded state. The model incorporated information about mass distribution and
length changes of Aβ and accounted for the co-existence of monomer, dimer, and aggregated
species. The model provided mechanisms for both generation and elongation of fibrils, and
was able to capture all the essential features of the experimental data.
The structure of the Aβ monomer is difficult to characterize due to its tendency to aggre-
gate. Experiments focusing on the understanding of physical structure of Aβ showed that they
are not necessarily homogenous in shape. Filament (3–4 nm in diameter) and fibril (8–10 nm
in diameter) structures have been observed in several electron microscopy and atomic force
microscopy experiments [39, 40, 26]. Furthermore, Malinchik et al. [41] suggested that fibers
are made of three to five laterally associated filaments. Fraser [42] reported on observing amy-
loid fibers made of five to six globular units, each with 2.5–3 nm in diameter. Finally, Reixach
et al. [43] showed that oligomers are formed from the aggregation of at most six monomers.
Mathematical models of the Aβ kinetics provide a clearer mechanistic understanding of the
amyloid fibril growth, improve our ability to design compounds that alter and modulate fibril
formation, and provide therapeutic potential venues for the AD.
This paper develops a discrete mathematical model for the aggregation of monomers to
oligomers and discusses a mechanism to reduce the production of oligomers. The model is
based on the assumption that soluble Aβ oligomers are the causative agents of AD. First, we
provide a brief review of chemical kinetics and then proceed to develop the discrete model. A
stability analysis follows which determines the aggregation condition. Finally, A formula for
the number of monomers that is required for producing oligomers is provided. In [44], Puri
and Li developed a continuous-time (differential equation) model focusing on the network
cross talk among microglia, neuron, and astroglia, and the corresponding pathological conse-
quence. However, in this work, we take a different approach (discrete) in modeling the aggre-
gation of β − Amyloid into diamers, triamers, etc., and finally into oligomers. The novelty of
our approach is the utilization of ideas from chemical kinetics [45] and population dynamics
[46], to develop a discrete-time model describing this process.
A brief review of chemical kinetics
In chemical kinetics [45], if A is the reactant and B is the product, so that A!B, then the aver-
age rate of the reaction describes the change in the concentration of either A or B, and is given
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Letting Δt = 1, we obtain from (3),
Bðtþ 1Þ   BðtÞ ¼   ðAðtþ 1Þ   AðtÞÞ ð4Þ
In general, for the reaction,
aAþ bB! cCþ dD ð5Þ
where a, b, c, d are the number of molecules of A, B, C, D respectively, we have,













The reaction rate law expression relates the rate of an elementary reaction to the concentration
of each reactant, that is
average rate of reaction ¼ K:Aa:Bb ð7Þ
where K is the reaction constant, to be determined experimentally.
The construction of the model: Making oligomers
In its simplest forms, Amyloid formation can be described by protein aggregation, involving
the misfolding of Aβ into soluble and insoluble assemblies [47, 48]. Kinetic studies have sug-
gested that the misfolding of monomeric Aβ has been shown to precede the formation of olig-
omers, which then serve as seeds for accelerated fibril growth, [49], as illustrated in Fig 1.
The two phases of Amyloid formation are shown: (i) nucleation phase, in which monomers
undergo misfolding and associate to form oligomeric nuclei, and (ii) elongation phase, in
which the oligomeric nuclei rapidly grow by further addition of monomers, forming larger
fibrils. As explained in [48], the nucleation phase occurs gradually and at a slower rate than the
elongation phase which proceeds faster being more favorable. A sigmoidal curve can thus
describe the process. Addition of more monomers (seeds) speeds up the process and induces
faster aggregate formation (blue curve). In contrast, the lack of monomers introduces lag time
and slows down the aggregation process.
We now proceed to the modeling part. We assume that (i) monomers of Aβ aggregate to
form diamers (2 monomers), triamers (3 monomers), . . ., etc. (ii) only monomers aggregate
with diamers, triamers, . . .. (iii) this process of aggregation is irreversible., and finally, (iv) olig-
omers are formed from the aggregation of six monomers.
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Let M1, M2, M3,. . .,Mn−1, denote the number of monomers, diamers, triamers,:. . ., respec-
tively. It is assumed that n monomers aggregate to make an oligomer as shown in Fig 1. A
mathematical scenario is illustrated in Table 1.
It is important to note that the change ΔM1 for each reaction are different. In Table 1 col-
umn 3, we determine the change in this concentration for each reaction. Adding ΔM1 for all
reactions, we get, the overall change for M1:
DM1ðtÞ ¼   2K1M1ðtÞM1ðt þ 1Þ   K2M2ðtÞM1ðt þ 1Þ   K3M3ðtÞM1ðt þ 1Þ     
Which can be written as,
DM1ðtÞ ¼   2K1M1ðtÞM1ðt þ 1Þ   M1ðt þ 1Þ
Pn  1
i¼2 KiMiðtÞ ð8Þ
Fig 1. The aggregation of β − Amyloid: From monomers to oligomers. See text for details. Adapted from [48].
https://doi.org/10.1371/journal.pone.0196402.g001
Table 1. Kinetics of monomers aggregation as a function of time.
Reaction Reaction rate Change in ΔM1
M1 + M1!M2   12 DM1 ¼ DM2 ΔM1(t) = −2K1M1(t)M1(t + 1)
M1 + M2!M3 −ΔM1 = −ΔM2 = −ΔM3 ΔM1(t) = −K2M2(t)M1(t + 1)





M1 + Mn−2!Mn−1 −ΔM1 = −ΔMn−2 = −ΔMn−1 ΔM1(t) = −Kn−2Mn−2(t)M1(t + 1)
https://doi.org/10.1371/journal.pone.0196402.t001
Modeling β-Amyloid aggregation
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Similarly, for i>1 at the ith reaction, we have,
M1 þMi ! Miþ1; i > 1
therefore, the overall change for Mi, i>1:
DMiþ1ðtÞ ¼ KiMiðtÞM1ðtÞ   Kiþ1M1ðtÞMiþ1ðt þ 1Þ ð9Þ




ðtÞ   K2M1ðtÞM2ðt þ 1Þ
DM3ðtÞ ¼ K2M1ðtÞM2ðtÞ   K3M1ðtÞM3ðt þ 1Þ
..
.
DMn  1ðtÞ ¼ Kn  2M1ðtÞMn  2ðtÞ   Kn  1M1ðtÞMn  1ðt þ 1Þ
Since monomers are produced by the body, we assume a source function that this is repre-
sented by f(M1). Hence the discrete model is finally given by







ðtÞ   K2M1ðtÞM2ðt þ 1Þ
DM3ðtÞ ¼ K2M1ðtÞM2ðtÞ   K3M1ðtÞM3ðt þ 1Þ
..
.
DMn  1ðtÞ ¼ Kn  2M1ðtÞMn  2ðtÞ   Kn  1M1ðtÞMn  1ðt þ 1Þ




. In case of no interaction, the first equation
becomes, M1 t þ 1ð Þ ¼
ðdþ1ÞgM1ðtÞ
gþdM1ðtÞ
, which is the popular Beverton-Holt model and is illustrated
in Fig 2.
The Beverton-Holt model [50] is a discrete-time population model which gives the popula-
tion size (density) M1(t + 1) as a function of the size (density) of the previous generation M1(t).
Note that (δ + 1) represents the average growth of monomer production with δ>0 and γ is the
carrying capacity. Fig 3 illustrates the growth rate behavior [50, 46].
Using this, we obtain,
M1 t þ 1ð Þ ¼
ðdþ 1ÞgM1ðtÞ
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M2 t þ 1ð Þ ¼
M2ðtÞ þ K1M21ðtÞ
1þ K2M1ðtÞ





Mn  1 t þ 1ð Þ ¼
Mn  1ðtÞ þ Kn  2M1ðtÞMn  2ðtÞ
1þ Kn  1M1ðtÞ
ð10Þ
The basic equilibria are the extinction point E
























Moreover, all the points on the surface M
1
¼ 0 are equilibrium points that are of no practi-
cal interest since in this case, no chemical reaction is present.
Stability analysis
As mentioned earlier, [43], it is accepted that 6 monomers are needed to aggregate to make
one oligomer. In model (10), let us assume that n = 6. Hence we have the two equilibria E

=
Fig 2. The cobweb diagram of the Beverton-Holt model of monomer’s production in the absence of aggregation.
The size of monomers increases over time and reaches its carrying capacity γ.
https://doi.org/10.1371/journal.pone.0196402.g002
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Þ. The Jacobian matrix of (10) is now given by
JðEÞ ¼
ðdþ 1Þ 0 0 0 0
0 1 0 0 0
0 0 1 0 0
0 0 0 1 0













































































































To determine the stability of M

, we are going to use the following result due to Gerschgorin
[51].
Fig 3. The figure shows the function M2 ¼
M1ðtþ1Þ
M1ðtÞ
(on the vertical axis) versus M1(t) (on the horizontal axis). The
growth rate decreases from δ + 1 when M1 is small, to γ and eventually close to zero.
https://doi.org/10.1371/journal.pone.0196402.g003
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Theorem (Gerschgorin)
Let A = (aij) be a k × k matrix. Let Si be the disk in the complex plane with center at aij, and
radius ri ¼
Pk
j6¼i jaijj. Then all eigenvalues of A lie in S ¼ [
k
i¼1Si.












































































ðdþ 1Þðdþ 6gK1 Þ
 
< 1 ð13Þ
























Ki  1 < Ki ð16Þ
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>   1 ð17Þ
1   Ki  1M

1







ðKi  1   KiÞ < 2 ð19Þ
which is true assuming (16).
Hence the condition that all eigenvalues λi, 2 i n − 1 lie inside the unit disk is Ki−1 Ki,
2 i n − 1
The following theorem summarizes the above stability analysis.
Theorem












and Ki−1 Ki for 2 i n − 1
Now to prevent the aggregation of monomers to oligomers and reduce the toxicity level of
the neuron cells, one should make the system unstable.






and, consequently, the equilibrium point M

is unstable, or (ii) using a suppressant to limit the
production of monomers to the effect that the net reproduction rate δ is reduced.
Another interesting problem is to determine exactly how many monomers are needed to
make an oligomer. As mentioned earlier, we followed the literature and assumed that this
number is 6.




to find the number of monomers needed to







Fig 4 shows the behavior of the number of monomers (n) needed to create an oligomer as a func-
tion of K1 (with gamma fixed; blue curve) and as a function of gamma (with K1 fixed; red curve).
As can be seen, to increase n, we can either increase γ or lower K1. By increasing n, one may
reduce the number of oligomers, and consequently, may decrease the likelihood of developing
the Alzheimer’s disease.
Conclusion
AD is an irreversible progressive degenerative disorder that is characterized by the loss of syn-
apses and neurons from the brain and by the presence of extracellular protein containing
Modeling β-Amyloid aggregation
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deposits, with β − Amyloid as the principal protein component. The presence of β − Amyloid
is strongly suggested to be a causative of neural degeneration as celebrated by the celebrated
Aβ hypothesis. β − Amyloid monomers aggregate to oligomers and in turn oligomers aggre-
gate to fibrils. In this paper, we have developed a discrete mathematical model for the aggrega-
tion of monomers to oligomers. The model is based on the assumption that oligomers are the
toxic stage of the aggregation, and is built using concepts from chemical kinetics and popula-
tion dynamics. Based on the model, we propose a mechanism to slow down the aggregation






Here, γ is the carrying capacity of the β − Amyloid, δ is its growth rate, and Ki is the reaction
constant of i monomers (for instance, K1 is for a monomer, K2 is for a diamer,. . .etc).









is the equilibrium state of monomers.
Fig 4. The variation of n, the number of monomer that aggregates to an oligomer, relative to K1 and γ increases or K1 decreases.
https://doi.org/10.1371/journal.pone.0196402.g004
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In this paper, we present a formula for the reduction of the aggregation of monomers to the
toxic oligomers, a process thought to contribute to the development of Alzheimer Disease. To
our knowledge, this is the first discrete mathematical modeling study that combines popula-
tion dynamics and kinetics principles to develop a prevention mechanism that would poten-
tially reduce the risk of Alzheimer Disease. We note that this is a mathematical model that has
not been tested or implemented in a clinical trial. We derive formulations for critical parame-
ters thought to affect the progression of the AD. Validating the model is beyond the scope of
this paper and is a possible venue for future follow-up work.
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